Natixis Advisors LLC raised its holdings in CME Group Inc. (NASDAQ:CME – Free Report) by 10.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 182,987 shares of the financial services provider’s stock after purchasing an additional 17,575 shares during the quarter. Natixis Advisors LLC owned 0.05% of CME Group worth $42,495,000 at the end of the most recent reporting period.
Several other hedge funds also recently added to or reduced their stakes in CME. SJS Investment Consulting Inc. boosted its stake in shares of CME Group by 570.6% during the 4th quarter. SJS Investment Consulting Inc. now owns 114 shares of the financial services provider’s stock worth $26,000 after acquiring an additional 97 shares in the last quarter. Truvestments Capital LLC purchased a new stake in shares of CME Group during the 3rd quarter worth about $26,000. Dunhill Financial LLC boosted its stake in shares of CME Group by 188.4% during the 3rd quarter. Dunhill Financial LLC now owns 124 shares of the financial services provider’s stock worth $27,000 after acquiring an additional 81 shares in the last quarter. Financial Life Planners purchased a new stake in shares of CME Group during the 4th quarter worth about $32,000. Finally, Knuff & Co LLC purchased a new stake in shares of CME Group during the 4th quarter worth about $33,000. 87.75% of the stock is owned by hedge funds and other institutional investors.
CME Group Stock Down 0.4 %
Shares of NASDAQ CME opened at $258.68 on Monday. The company has a 50 day simple moving average of $242.80 and a 200-day simple moving average of $232.58. The company has a market capitalization of $93.22 billion, a P/E ratio of 26.75, a P/E/G ratio of 6.76 and a beta of 0.53. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.01 and a quick ratio of 1.02. CME Group Inc. has a 1 year low of $190.70 and a 1 year high of $263.65.
CME Group announced that its board has authorized a stock buyback plan on Thursday, December 5th that authorizes the company to repurchase $3.00 billion in shares. This repurchase authorization authorizes the financial services provider to buy up to 3.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its shares are undervalued.
CME Group Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 26th. Stockholders of record on Friday, March 7th will be issued a dividend of $1.25 per share. The ex-dividend date of this dividend is Friday, March 7th. This represents a $5.00 dividend on an annualized basis and a dividend yield of 1.93%. This is an increase from CME Group’s previous quarterly dividend of $1.15. CME Group’s dividend payout ratio (DPR) is currently 51.71%.
Insider Transactions at CME Group
In related news, insider Hilda Harris Piell sold 3,984 shares of CME Group stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $250.47, for a total value of $997,872.48. Following the completion of the sale, the insider now owns 27,046 shares in the company, valued at approximately $6,774,211.62. This trade represents a 12.84 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Suzanne Sprague sold 1,500 shares of CME Group stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $256.83, for a total transaction of $385,245.00. Following the completion of the sale, the chief operating officer now owns 8,036 shares of the company’s stock, valued at $2,063,885.88. This trade represents a 15.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 17,076 shares of company stock worth $4,271,496 in the last 90 days. Insiders own 0.30% of the company’s stock.
Analysts Set New Price Targets
CME has been the topic of several recent analyst reports. Citigroup lowered shares of CME Group from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $255.00 to $250.00 in a research note on Monday, January 6th. Raymond James raised shares of CME Group from a “market perform” rating to an “outperform” rating and set a $287.00 price target on the stock in a research note on Monday, March 10th. Barclays raised their price target on shares of CME Group from $257.00 to $263.00 and gave the company an “equal weight” rating in a research note on Thursday, February 13th. Morgan Stanley raised their price target on shares of CME Group from $256.00 to $263.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 19th. Finally, Keefe, Bruyette & Woods raised their price target on shares of CME Group from $256.00 to $257.00 and gave the company a “market perform” rating in a research note on Friday, February 14th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $238.93.
Read Our Latest Research Report on CME
CME Group Company Profile
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
Featured Articles
- Five stocks we like better than CME Group
- Insider Trading – What You Need to Know
- How to Build the Ultimate Everything ETF Portfolio
- What is a Death Cross in Stocks?
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Why Are These Companies Considered Blue Chips?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.